FDA Advisory Panel Endorses Approval of Alzheimerβs Drug Made by Eli Lilly
10 June 2024 at 17:05
The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.
Β© Shannon Stapleton/Reuters
Β© Joe Buglewicz for The New York Times
Β© Kenny Holston/The New York Times